What I have: early satiety · six · dulaglutide.
I am trying to do this correctly the first time rather than learn it by getting it wrong.
I have already made one mistake here that cost me a vial, so I am being deliberately careful.
What is the correct sequence, and where is the step that people usually skip?
Week 6 is day 42: on a four-week ladder that is week 2 of dose step 2, and — at the seven-day half-life this class runs on — 6 half-lives in. Steady state is about five half-lives, so day 35 is where the concentration stops climbing on its own. Day 42 is 1 weeks past it, which means the level is no longer the variable. That distinction is most of the question: at week 2 of a step, an effect that is still accumulating is indistinguishable from one that is not resolving unless you know which side of day 35 you are on. Early satiety is the mechanism rather than a side effect of it — delayed gastric emptying is the intended pharmacology — so the question the week number helps with is whether it is proportionate, not whether it is expected. Dose decisions are made under supervision, and nothing here is medical advice.
Start with which symptom predominates, because the management diverges sharply even though the mechanism does not.
Discontinuation for gastrointestinal effects in the trials runs in the low single-figure percentages, which means the great majority of people who experience these effects continue.
| Event | Active arm | Placebo arm | Timing |
|---|---|---|---|
| Nausea | 40–45 % | 15–20 % | Peaks 1–2 wk after each step |
| Vomiting | 15–25 % | 5–8 % | Follows nausea |
| Diarrhoea | 20–30 % | 10–15 % | Early, variable |
| Constipation | 20–25 % | 8–12 % | Later onset, persistent |
| Discontinuation for GI events | 4–7 % | 1–2 % | Mostly during escalation |
Ranges span agents and doses; read the specific prescribing information for a specific figure.
Mechanically, anticipating a slower-than-label titration from the start is a legitimate approach and costs only time, since the exposure ceiling is the same.
Four-weekly titration intervals in the licensed schedules were selected to allow tolerance between escalations.
Smaller meals, less fat, fluids between rather than with. In that order.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsPut another way, diarrhoea and constipation both occur, which surprises people until they consider how many mechanisms are involved.
Symptom prevalence in trials, broadly: nausea a quarter to a half, diarrhoea and constipation each roughly ten to twenty per cent, vomiting rather less, with all rates rising with dose.
Symptoms that appear for the first time at a stable dose after months are not the ordinary pattern and warrant looking for another explanation.
Gastric emptying studies in this class quantify the delay directly and document its attenuation with continued exposure to the long-acting agents.
New symptoms at a stable dose after months need a different explanation.
Answer first: the gastrointestinal effects in this class share one mechanism — slowed gastric emptying plus central signalling — and present as nausea, fullness, reflux, constipation or diarrhoea depending on the person.
Reflux occurs because a slower-emptying stomach retains volume for longer against a lower oesophageal sphincter that has not changed. Smaller meals and not lying down within a few hours are the direct responses.
The practical hierarchy of interventions: slow the titration, reduce meal size, reduce fat, separate fluids from meals, and only then consider symptomatic treatment.
Trial-reported incidence and discontinuation rates for gastrointestinal effects are published per agent and per dose and are the appropriate figures to quote.
Most people who report these effects continue. The discontinuation rate is low.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.